Intervention
Enasidenib
ClinicalTrials.gov intervention label
Clinical trials
1 shownCommon conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Anatomic Stage IV Breast Cancer AJCC v81Anemia1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1Ann Arbor Stage IV Hodgkin Lymphoma1Ann Arbor Stage IV Non-Hodgkin Lymphoma1Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Castration-Resistant Prostate Carcinoma1Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Hematopoietic and Lymphoid System Neoplasm1Locally Advanced Pancreatic Adenocarcinoma1Metastatic Breast Carcinoma1Metastatic Malignant Solid Neoplasm1Metastatic Pancreatic Adenocarcinoma1Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis1Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable1Primary Myelofibrosis1Recurrent Acute Lymphoblastic Leukemia1Recurrent Acute Myeloid Leukemia1Recurrent Chronic Lymphocytic Leukemia1Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Recurrent Hematologic Malignancy1Recurrent Hodgkin Lymphoma1
Leading sponsors
Trial status mix
TERMINATED1
Phase mix
PHASE11
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.